Patents by Inventor LUIS L. MANGUAL ARBELO

LUIS L. MANGUAL ARBELO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220387095
    Abstract: Damaged, diseased, abnormal, obstructive, cancerous or undesired neural tissue treated by delivering specialized pulsed electric field (PEF) energy to target tissue areas. In some instances, the target tissue includes a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue. Most brain and spinal cord tumors develop from glial cells. These tumors are sometimes referred to as a group called gliomas. They arise from the supporting cells of the brain, called the glia. These cells are subdivided into astrocytes, ependymal cells and oligodendroglial cells (or oligos). One difficulty in the treatment of gliomas is that they are behind the blood-brain barrier (BBB) and blood-tumor barrier (BTB) which leads to poor delivery of anti-cancer drugs or immune agents to the tumor-infiltrated brain.
    Type: Application
    Filed: May 17, 2022
    Publication date: December 8, 2022
    Applicant: Galvanize Therapeutics, Inc.
    Inventors: Robert E. Neal, II, William S. Krimsky, Seth S. Gleiman, Nicholas S. Mercer, Timothy J. O'Brien, Quim Castellvi, Jonathan R. Waldstreicher, Kevin J. Taylor, Luis L. Mangual Arbelo
  • Publication number: 20220133401
    Abstract: Devices, systems and methods are provided for treating conditions of the reproductive tract. A number of conditions can afflict the lining and cell layers deeper within the anatomical structures. For example, cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is a condition involving abnormal growth of cells on the surface of the cervix that could potentially lead to cervical cancer in situ (CIS). Other conditions include human papillomavirus (HPV)-related cervical disease, various endometrial diseases, acute and chronic cervicitis, and various infections (e.g. trichomoniasis) to name a few. In some embodiments, treatments eliminate diseased, damaged, abnormal or otherwise undesired cells leaving the tissue framework intact. This allows the tissue to regenerate in a normal fashion, avoiding the formation of scar tissue.
    Type: Application
    Filed: January 13, 2022
    Publication date: May 5, 2022
    Applicant: Galary, Inc.
    Inventors: Timothy J. O'BRIEN, Quim CASTELLVI, Luis L. Mangual ARBELO, Jonathan R. WALDSTREICHER, Seth S. GLEIMAN, Nicholas S. MERCER, Kevin J TAYLOR, Robert E. NEAL, II, William S. KRIMSKY, Armaan G. VACHANI
  • Publication number: 20220104875
    Abstract: Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.
    Type: Application
    Filed: October 15, 2021
    Publication date: April 7, 2022
    Applicant: Galary, Inc.
    Inventors: SETH S. GLEIMAN, NICHOLAS S. MERCER, TIMOTHY J. O'BRIEN, JONATHAN R. WALDSTREICHER, KEVIN J. TAYLOR, LUIS L. MANGUAL ARBELO, ROBERT E. NEAL, WILLIAM SANFORD KRIMSKY, QUIM CASTELLVI